



## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/517,956	12/13/2004	Shuji Hinuma	62582(46342)	7274	
21874 75	590 02/01/2006		EXAMINER		
EDWARDS & ANGELL, LLP			ULM, JOHN D		
P.O. BOX 5587 BOSTON, MA			ART UNIT	PAPER NUMBER	
BOSTON, WIN 02203			1649		

DATE MAILED: 02/01/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

		Applica	ation No.	Applicant(s)				
Office Action Summary		10/517	,956	HINUMA ET AL.				
		Examir	ner	Art Unit				
		John D.		1649				
Period fo	The MAILING DATE of this communic or Reply	cation appears on	the cover sheet w	ith the correspondence ac	idress			
WHIC - Externafter - If NC - Failu Any	ORTENED STATUTORY PERIOD FO CHEVER IS LONGER, FROM THE MA nsions of time may be available under the provisions of SIX (6) MONTHS from the mailing date of this commu- to period for reply is specified above, the maximum state are to reply within the set or extended period for reply we reply received by the Office later than three months affed patent term adjustment. See 37 CFR 1.704(b).	ALING DATE OF f 37 CFR 1.136(a). In no nication. utory period will apply and rill, by statute, cause the a	THIS COMMUNIO event, however, may a red will expire SIX (6) MON application to become AB	CATION. reply be timely filed ITHS from the mailing date of this of BANDONED (35 U.S.C. § 133).				
Status								
1)	Responsive to communication(s) filed	I on			·			
2a)□	This action is <b>FINAL</b> . 2	of the control of the						
3)□	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is							
	closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.							
Dispositi	ion of Claims							
4)⊠	Claim(s) 1-46 is/are pending in the ap	plication.						
	4a) Of the above claim(s) is/are withdrawn from consideration.							
5)	Claim(s) is/are allowed.							
6)□	Claim(s) is/are rejected.							
7)	Claim(s) is/are objected to.							
8)⊠	Claim(s) <u>1-46</u> are subject to restrictio	n and/or election r	requirement.					
Applicati	on Papers		•					
9)	The specification is objected to by the	Examiner.	·	•				
10)	The drawing(s) filed on is/are:	a) accepted or	b) ☐ objected to	by the Examiner.				
	Applicant may not request that any object	tion to the drawing(s	s) be held in abeyar	nce. See 37 CFR 1.85(a).				
	Replacement drawing sheet(s) including	he correction is req	uired if the drawing	(s) is objected to. See 37 C	FR 1.121(d).			
11)	The oath or declaration is objected to	by the Examiner.	Note the attached	d Office Action or form P	ΓΟ-152.			
Priority ι	under 35 U.S.C. § 119							
	Acknowledgment is made of a claim for	or foreign priority (	under 35 U.S.C. §	§ 119(a)-(d) or (f).				
a)	☐ All b)☐ Some * c)☐ None of:		•					
	1. Certified copies of the priority of							
	2. Certified copies of the priority of			• •				
	3. Copies of the certified copies o			received in this National	Stage			
* 0	application from the Internation See the attached detailed Office action	•	, ,,	rancised				
	see the attached detailed Office action	ior a list of the ce	itilied copies not	received.				
A44- 1	<i>u</i> .							
Attachmen  1) Notice	t(s) e of References Cited (PTO-892)		4) 🗀 Internation (	Summon (DTO 442)				
	e of References Cited (P10-892) e of Draftsperson's Patent Drawing Review (PT	O-948)	Paper No(s	Summary (PTO-413) s)/Mail Date				
3) 🔲 Infor	nation Disclosure Statement(s) (PTO-1449 or F r No(s)/Mail Date	•	5)  Notice of II	nformal Patent Application (PT0 —.	O-152)			

Art Unit: 1649

## **DETAILED ACTION**

Claims 1 to 46 are pending in the instant application.

## Election/Restrictions

Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group I, claims 1 to 7, 34 and 35, drawn to an **assay** employing "humanin" and a G protein-coupled receptor therefore.

Group II, claims 8, 9, 11 to 14, 36, 37 and 45, only in so far as they relate to an agonistic compound of unspecified constitution.

Group III, claims 8, 10, 11, 37 and 45, only in so far as they relate to an antagonistic compound of unspecified constitution.

Groups IV to VII, claims 15 to 17, 36 and 37, only in so far as they relate to a receptor protein comprising one of the four different amino acid sequences recited therein, and methods of use. Group IV, for example, consists of claims 15 to 17, 36 and 37 only in so far as they relate to SEQ ID NO:1. Group VII consists of claims 15 to 17, 36 and 37 only in so far as they relate to SEQ ID NO:14.

Group VIII to XI, claims 18 to 22, 25, 26, 30, 31, 36 and 37, only in so far as they relate to a polynucleotide encoding one of the four amino acid sequences recited therein, and methods of use.

Art Unit: 1649

Group XII to XV, claims 23 and 24, only in so far as they relate to an antibody that binds to a receptor protein comprising one of the four different amino acid sequences recited therein.

Group XVI, claims 27 to 29, 32 and 33, drawn to a compound of unspecified constitution that increases the expression level of a protein.

Group XVII, claims 38 to 44 and 46, drawn to "Humanin" and a method of use.

The inventions listed as Groups I to XVII do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: The assay of invention I is distinguished from the art by the combination of Humanin with a receptor therefore because the text on pages 2 to 4 of the instant application concedes Humanin and the Humanin receptors FPRL-1 and FPRL-2 to the prior art. This combination is not present in any of inventions I to XVII. The compounds of invention II to XVII do not reflect a single inventive concept because they lack a corresponding special technical feature that distinguishes them as a group from the prior art. The four different receptor proteins that define inventions IV to VII, for example, are related to one another because they are Humanin receptors that are members of the G proteincoupled receptor family. They are not distinguished as a group from the prior art because the instant application has admitted that the G protein-coupled Humanin receptors FPRL-1 and FPRL-2 were known in the art before the making of the instant invention.

This application contains claims directed to more than one disclosed species of receptor protein, as recited in claim 1, for example, and more than one disclosed species of Humanin, as recited in claim 39. These species are deemed to lack unity of invention because they are not so linked as to form a single general inventive concept under PCT Rule 13.1. The different receptors recited in the claims do not reflect a common inventive concept for those reasons given above. The species of Humanin do not reflect a common inventive concept because the specification has conceded Humanin to the prior art and all proteins produced in living systems are initially synthesized with a formyl-methionine at the amino terminus.

Applicant is required, in reply to this action, to elect a single species of receptor protein and Humanin to which the claims shall be restricted if no generic claim is finally held to be allowable. The reply must also identify the claims readable on the elected species, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered non-responsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

Art Unit: 1649

Applicant is advised that the reply to this requirement to be complete must

include an election of the invention to be examined even though the requirement be

traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected

invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one

or more of the currently named inventors is no longer an inventor of at least one claim

remaining in the application. Any amendment of inventorship must be accompanied by

a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the

examiner should be directed to John D. Ulm whose telephone number is (571) 272-

0880. The examiner can normally be reached on 9:00AM to 5:30PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's

supervisor, Janet Andres can be reached on (571) 272-0867. The fax phone number

for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the

Patent Application Information Retrieval (PAIR) system. Status information for

published applications may be obtained from either Private PAIR or Public PAIR.

Status information for unpublished applications is available through Private PAIR only.

For more information about the PAIR system, see http://pair-direct.uspto.gov. Should

you have questions on access to the Private PAIR system, contact the Electronic

Business Center (EBC) at 866-217-9197 (toll-free).

Art Unit: 1649

Page 6

JOHN ULM PRIMARY EXAMINER GROUP 1800